Evidence map›Paper›PMID 38865673›Full record

ArticleJCO precision oncology2024

Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.

Erica S Tsang, Mallika S Dhawan, Romain Pacaud, Scott Thomas, Jennifer Grabowsky, Lauren Wilch, Silpa Karipineni, Robin Kate Kelley, Andrew H Ko, Eric Collisson and 4 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Erica S TsangDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-2317-2721
Mallika S DhawanDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.
Romain PacaudDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-4352-0976
Scott ThomasDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.
Jennifer GrabowskyDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-4871-0741
Lauren WilchDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.
Silpa KaripineniDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.
Robin Kate KelleyDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-1984-2430
Andrew H KoDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.
Eric CollissonDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-2829-355X
Jocelyn S ChapmanDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-4260-3016
Stefanie UedaDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-4359-0966
Emily K BergslandDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.ORCID 0000-0001-7754-6552
Pamela MunsterDivision of Hematology and Oncology, University of California San Francisco, San Francisco, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCombining poly ADP-ribose polymerase (PARP) and topoisomerase I inhibitors has demonstrated synergistic effects in in vivo models. This phase I trial evaluated rucaparib and irinotecan in metastatic solid tumors with homologous recombination deficiency.

methodsThis study enrolled patients in three cohorts to determine the tolerability and preliminary efficacy of (1) rucaparib 400 mg PO twice a day (days 1-7, 15-21) and irinotecan 65 mg/m

resultsTwenty patients were enrolled: 95% with previous platinum, 40% with previous irinotecan, and 20% with previous PARP inhibitor. The maximally tolerated was determined as rucaparib 400 mg twice a day days 1-7 and irinotecan 100 mg/m

conclusionPulse dosing of rucaparib and once every 3 weeks irinotecan was well tolerated for up to 18 months with durable responses in

Indexed as

IndolesIrinotecanNeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinFemaleHomologous RecombinationHumansMaleMiddle AgedMutationNeoplasm MetastasisPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanIndolesIrinotecanPoly(ADP-ribose) Polymerase Inhibitorsrucaparib

Identifiers

PMID38865673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.